Neil Gibson, PhD

< back

Neil Gibson, PhD is President and CEO of PDI Therapeutics and Senior Vice President of COI Pharmaceuticals. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development, and commercialization of four approved oncology drugs (including temozolomide, sorafenib, erlotnib, and crizotinib). Dr Gibson’s extensive oncology experience includes being CSO of Pfizer Oncology Research Unit, CSO of Regulus Therapeutics, and CSO of OSI Pharmaceuticals.  Dr. Gibson also serves on the board of TCR2, a new public company focused on T-cell therapies.